News | May 10, 2009

Medtronic, Johnson and Johnson Reach Agreement on Royalty Disputes

May 10, 2009 - Medtronic Inc. Friday announced the settlement of all royalty disputes with Johnson and Johnson (J&J) that concern Medtronic’s licensed use of the Palmaz, Schatz and Pinchuk patents relating to coronary angioplasty stent design and balloon material patents.

The agreement ends all current and potential disputes between the two parties under their 1997 settlement and license agreement. Other disputes between the parties are unaffected by this settlement, Medtronic said.

“Resolving these disputes allows us to focus our resources on the development of new products that will improve the quality of care for people with cardiovascular disease,” said Scott Ward, president of the CardioVascular business and senior vice president at Medtronic.

Medtronic paid J&J $270 million for all alleged royalty claims against its products under a 1997 settlement and license agreement between the parties. Medtronic will reflect the settlement as a one-time charge in its fourth fiscal quarter, ending in April 2009.

For more information: www.medtronic.com

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Sponsored Content | Videos | EP Lab| May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init